Abstract:At least 10% of all breast cancer is estimated to result from an inherited predisposition.1 Mutations in 2 genes, BRCA1 and BRCA2, have been shown to confer a very high risk for breast and ovarian cancer.2 A significant proportion of familial cases, however, cannot be attributed to BRCA1 or BRCA2 mutations,3, 4 and additional breast cancer susceptibility gene(s) may account for a fraction of high-risk families. Recently, it was suggested that a novel protein, BACH1, a member of the DEAH helicase family could be one such gene.5 BACH1 maps to 17q22 and consists of 20 exons, spanning over 180 kb of genomic sequence. It encodes a 130 kDa polypeptide that binds directly to BRCT repeats of BRCA1 and interferes with normal double-strand break repair in a manner that was dependent on the BRCA1 binding.5 Furthermore, 2 germ-line missense mutations were detected in 65 individuals with breast cancer (1 in familial and 1 with early-onset breast cancer) lacking mutations in both BRCA1 and BRCA2. None of them occurred in any of 200 normal controls. We have evaluated a putative contribution of this locus to breast cancer susceptibility by analyzing 197 breast cancer families in which we did not detect BRCA1 and BRCA2 mutations (Table I). The exon 11 of BRCA1 was screened on genomic DNA using PTT and the remaining exons were analyzed using SSCP, CDGE or direct sequencing.4, 6 The BRCA2 gene was screened by PTT using genomic DNA for exon 10 and 11 and using RNA for all other exons, or the entire gene was screened using direct sequencing of genomic DNA.4, 7 High-risk breast cancer families were identified and collected through the Cancer Counseling Clinic at the Karolinska Hospital. The families were selected if 2 or more close relatives were affected with breast cancer, and if the proband was counseled a 2–4 times increased risk for the disease compared to the normal population. Blood samples were obtained from the affected and unaffected family members with informed consent. Linkage analysis involved 285 members of 102 breast cancer families, including 245 breast cancer patients. The average age at diagnosis in the patients was 54.7 years old, ranging between 30–72. Nine of the families were breast-ovarian cancer families. Additional 95 patients with a family history of breast cancer, negative for BRCA1 and BRCA2 mutations, were selected to be screened for mutations in the BACH1 gene. Control females were mothers of Swedish patients with IgA deficiency ascertained as described previously8 and apparently unrelated blood donors drawn from the Swedish population. Genotyping was carried out using 19 fluorescent-labeled microsatellite markers on chromosome 17 (D17S1308; D17S1845; D17S1810; D17S1298; D17S1832; D17S974; D17S1303; D17S969; D17S921; D17S122; D17S1294; D17S1293; D17S1299; D17S809;D17S1290; D17S31B11; D17S1301; D17S784; D17S928), including 3 markers flanking the BACH1 gene (underlined). The amplified fragments were analyzed on an ABI377 automated sequencer (Applera, USA), together with internal size standard. The gels were analyzed with GENESCAN (v.3.1) and GENOTYPER (v.2.0) software packages (Applera). The average heterozygosity of markers was 0.76 with an average intermarker genetic distance of 7.8 cM. Nonparametric and multipoint linkage analysis was performed by using Genehunter (v.2.0) program.9 The genetic linkage analysis showed negative multipoint nonparametric LOD scores (NPL) for markers around BRCA1 and BRCA2 in 73 of 102 breast cancer and breast-ovarian cancer families. Only 29 families, including 3 early onset breast-ovarian cancer families, showed a positive NPL for markers flanking the BACH1 locus. A positive NPL indicates that the affected individuals in the pedigree share alleles at the analyzed loci in excess, which makes this region more likely to harbor a predisposing gene. Thus, the 29 families were selected and screened for germline mutations in the BACH1 gene, together with additional 95 familial breast cancer cases without detectable BRCA1 and BRCA2 mutations (Table I). Twenty-four segments of BACH1 coding exons and flanking intronic sequences were amplified from genomic DNA. The average size of PCR products was 247 bp, with a range of 164–331 bp. Oligonucleotide primers and PCR conditions are shown at http://www.biosci.ki.se/fam/res/BACH1.htm. The PCR-SSCP analysis and nucleotide sequencing was carried out as described.10 The PCR-SSCP analysis showed 4 different alterations. Three alterations turned out to be known polymorphisms (Table II), 5 whereas 1 alteration was a 517C-T transition not previously reported (Table II). This rare variant, which results in Arg173Cys substitution in the putative nuclear localization signal of BACH1, as predicted by PSORTII,11 was found in a family where 5 women were diagnosed with breast cancer. The variant was identified in 1 woman with breast cancer at age 51 but was not shared by her daughter who had breast cancer at age 45. Although this alteration did not segregate with disease in this family, it might still represent a weak disease-predisposition allele in the general population. To address this question, unrelated breast cancer patients and control females from the same population were examined. Three of 478 Swedish breast cancer patients (0.6%) and 2 of 315 Swedish controls (0.6%) were found to be heterozygous for this transition. No homozygotes were identified and there was no significant deviation from Hardy-Weinberg equilibrium (p > 0.05). These results suggested a similar allele/genotype frequency in affected and control individuals (p > 0.05), consistent with this alteration being a rare polymorphism that confers no detectable risk to breast cancer. Because of the low frequency of the variant allele, however, functional and larger association studies will be needed to elucidate a putative significance of this polymorphism in breast cancer. The families studied were previously screened for BRCA1-2 using various techniques, including PTT, SSCP, CDGE or by direct sequencing of all exons for both genes. Regardless of methods used, the frequency of BRCA-mutations in this cohort of patients has been low.4 At the same time, the age of onset of familial breast cancer in the Stockholm region is not, in contrast to what has been described in familial breast cancer in general, very much different from the age of onset in sporadic cases.12 The study involves a proportion of families with only 2 close relatives with breast cancer consistent with an increased susceptibility for disease, but also consistent with a genetic trait with low penetrance. In some of the families it is possible that these 2 cases were sporadic and occurred by chance. However, these families constitute a minority (20%), which is why this could not be the explanation for the lack of mutations found in this study. In conclusion, we found no BACH1 mutation in this highly selected family material, which would be predicted to be enriched for mutated cases by our linkage and family data, should BACH1 be an important breast cancer susceptibility gene. Recently, it was suggested that a few moderately strong genes and large number of weak genes together were responsible for breast cancer,2 thus not excluding the involvement of BACH1 in rare cases of breast- and ovarian cancer. Comparing the allelic and genotype frequency of BACH1 variants between much large numbers of breast cancer cases and matched normal population with minimized influence of the population stratification are needed to address a putative influence of this gene. Yours Sincerely, Liping LUO, Haixin LEI, Quan DU, Anna VON-WACHENFELDT, Ingrid KOCKUM, Holger LUTHMAN, Igor VORECHOVSKY and ANNIKA LINDBLOM* We thank the patients and their family members for cooperation.

Abstract:To the Editor: Ray and Weeks (Ray and Weeks, 2005Ray A Weeks DE No convincing evidence of linkage for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2005; 76 (in this issue): 705-707Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar [in this issue]) discussed some concerns about the statistical methodology of our genomewide linkage-scan study that identified a novel susceptibility locus for restless legs syndrome (RLS) on chromosome 9p24-22 (Chen et al. Chen et al., 2004Chen S Ondo WG Rao S Li L Chen Q Wang Q Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2004; 74: 876-885Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar). Before we systematically address their concerns, it is important to note that the 9p24-22 RLS locus has been replicated in a large family from Germany, with a significant LOD score found by an independent research group (J. Winkelmann, personal communication). This independent replication in a different study population has strongly validated our initial linkage finding. The Genetic Component of RLS: We are aware of the issue of a bias in estimation of familial correlations and heritability in a population enrolled for genetic studies. Therefore, we clearly stated this in our article (e.g., in the “Results” section, we noted, “The derived heritability…was 0.60, which indicates that RLS is a highly heritable trait in this ascertained cohort,” and, in the “Discussion” section, we noted, “It is important to note that familial correlations and heritability were estimated for an ascertained cohort, and the results may not be generalizable to the RLS population at large” [Chen et al. Chen et al., 2004Chen S Ondo WG Rao S Li L Chen Q Wang Q Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2004; 74: 876-885Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar, pp. 881 and 882]). Since the sampling schemes for the recruited RLS pedigrees are complicated and cannot be described by a single form of ascertainment, a formulated correction for ascertainment bias was not undertaken because of the lack of an appropriate method and software package. Nevertheless, our conclusion about the genetic nature of the disease was based on the analysis of diverse types of relative pairs. A large number of relative pairs of more remote types (i.e., second-, third-, and fourth-degree relations) were used for the inference, and these data might be less influenced by the ascertainment. We agree that familial risk-ratio estimation by use of the ascertained cohort could be biased, and a high population prevalence of 12% was thus used to obtain a conservative estimate. The determination of the genetic component of a complex human disease will perhaps continue to be a critical issue, since human pedigrees are often ascertained from clinical settings, and the sampling schemes may not be defined by a single ascertainment form. Nevertheless, genetic analysis of the collected samples for evidence of genetic factors, as a requisite step toward identification of disease genes, cannot be ignored. Without familial aggregation in which genetic factors play an important role, the expense and effort involved in further gene mapping and cloning would be wasted (Farrer and Cupples Farrer and Cupples, 1998Farrer LA Cupples LA Determining the genetic component of a disease.in: Haines JL Pericak-Vance MA Approaches to gene mapping in complex human diseases. Wiley-Liss, New York1998: 93-129Google Scholar). Model-Free Linkage Analysis: Ray and Weeks (Ray and Weeks, 2005Ray A Weeks DE No convincing evidence of linkage for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2005; 76 (in this issue): 705-707Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar) were concerned about our reporting of statistical significance. However, their arguments, which are based on the criteria of Lander and Kruglyak (Lander and Kruglyak, 1995Lander E Kruglyak L Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.Nat Genet. 1995; 11: 241-247Crossref PubMed Scopus (4381) Google Scholar) and rough transformation between different statistics through only the link of a P value (see table 1 in Ray and Weeks Ray and Weeks, 2005Ray A Weeks DE No convincing evidence of linkage for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2005; 76 (in this issue): 705-707Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar), may not be the most appropriate. First, Lander and Kruglyak’s criteria for genomewide significance were based on a dense map and on complete information extraction, which do not apply to our experiment, which had a less dense marker map (10-cM density, on average) and a fraction of missing genotypes. Using extensive simulations, Wiltshire et al. (Wiltshire et al., 2002Wiltshire S Cardon LR McCarthy MI Evaluating the results of genomewide linkage scans of complex traits by locus counting.Am J Hum Genet. 2002; 71: 1175-1182Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar) demonstrated that the criteria proposed by Lander and Kruglyak (Lander and Kruglyak, 1995Lander E Kruglyak L Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.Nat Genet. 1995; 11: 241-247Crossref PubMed Scopus (4381) Google Scholar) were too stringent for an initial 10-cM genome scan. Second, direct translation of a P value for different statistics can be criticized because of the high reliance of P values on sample sizes (Witte et al. Witte et al., 1996Witte JS Elston RC Schork NJ Genetic dissection of complex traits.Nat Genet. 1996; 12: 355-356Crossref PubMed Scopus (88) Google Scholar), especially for a small-to-medium sample size like that of our study. Third, a nominal P value derived from the asymptotic distribution of a linkage statistic can be different from the estimate obtained from permutation. In other words, the asymptotic distribution of a statistic can deviate substantially from the observed value, especially for small sample sizes. Fourth, the nonparametric linkage (NPL) statistic used in our genomewide scan is deemed to be quite conservative, meaning that P values of .05 occur less often than expected (Haines Haines, 1998Haines JL Affected relative pair analysis.in: Haines JL Pericak-Vance MA Approaches to gene mapping in complex human diseases. Wiley-Liss, New York1998: 305-321Google Scholar). Thus, direct exchange between LOD and NPL measures is highly questionable. Since unified criteria for significant and suggestive linkages based on NPL scores have not been described in the literature, we defined NPL scores of ⩾3.0 as significant evidence of linkage and scores of ⩾2.0 as suggestive evidence of linkage on the basis of the nominal empirical P values. Similar criteria have been used by others (Kaminen et al. Kaminen et al., 2003Kaminen N Hannula-Jouppi K Kestila M Lahermo P Muller K Kaaranen M Myllyluoma B Voutilainen A Lyytinen H Nopola-Hemmi J Kere J A genome scan for developmental dyslexia confirms linkage to chromosome 2p11 and suggests a new locus on 7q32.J Med Genet. 2003; 40: 340-345Crossref PubMed Scopus (104) Google Scholar; Laivuori et al. Laivuori et al., 2003Laivuori H Lahermo P Ollikainen V Widen E Häivä-Mällinen L Sundström H Laitinen T Kaaja R Ylikorkala O Kere J Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families.Am J Hum Genet. 2003; 72: 168-177Abstract Full Text Full Text PDF PubMed Scopus (120) Google Scholar; Friedrichsen et al. Friedrichsen et al., 2004Friedrichsen DM Stanford JL Isaacs SD Janer M Chang BL Deutsch K Gillanders E Kolb S Wiley KE Badzioch MD Zheng SL Walsh PC Jarvik GP Hood L Trent JM Isaacs WB Ostrander EA Xu J Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.Proc Natl Acad Sci USA. 2004; 101: 1939-1944Crossref PubMed Scopus (18) Google Scholar; Middleton et al. Middleton et al., 2004Middleton FA Pato MT Gentile KL Morley CP Zhao X Eisener AF Brown A Petryshen TL Kirby AN Medeiros H Carvalho C Macedo A Dourado A Coelho I Valente J Soares MJ Ferreira CP Lei M Azevedo MH Kennedy JL Daly MJ Sklar P Pato CN Genomewide linkage analysis of bipolar disorder by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay: a comparison with microsatellite marker assays and finding of significant linkage to chromosome 6q22.Am J Hum Genet. 2004; 74: 886-897Abstract Full Text Full Text PDF PubMed Scopus (146) Google Scholar). Most importantly, our claim of significant linkage at the 9p RLS locus was based on multiple lines of evidence from NPL analysis, Haseman-Elston sib-pair regression (P value at the peak <10−5; authors' unpublished data), and model-based linkage analysis.Table 1Revised Pairwise LOD Scores between RLS and Chromosome 9p24-22 Markers Obtained by Model-Based Linkage Analysis in Two Extended Kindreds with RLSLOD Score at θ =Marker and Kindred.00.05.10.20.30.40D9S1779: 40004.00.00.00.00.00.00 40015−1.32.11.24.20.05−.03 Total−1.32.11.24.20.05−.03D9S1871: 40004.30.28.25.20.14.08 400151.901.751.591.25.88.47 Total2.202.031.841.451.02.55D9S2169: 40004.60.56.51.40.29.16 400151.871.701.531.17.78.38 Total2.472.262.041.571.07.54D9S286: 400041.491.361.22.92.58.25 400152.041.861.681.31.91.48 Total3.533.222.902.231.49.73D9S168: 40004.00.00.00.00.00.00 400151.871.701.531.16.78.37 Total1.871.701.531.16.78.37D9S268: 40004.18.10.02−.11−.15−.10 400151.541.411.27.99.69.35 Total1.721.511.29.88.54.25D9S274: 400041.191.07.93.66.38.13 400151.911.751.591.25.88.48 Total3.102.822.521.911.25.61D9S1839: 40004.00.00.00.00.00.00 40015.80.70.60.40.21.06 Total.80.70.60.40.21.06D9S162: 40004−1.41−.18.02.12.07.00 400152.041.881.701.31.92.47 Total.631.701.721.43.99.47D9S1121: 40004−1.95−1.24−.80−.40−.23−.13 40015.15.13.10.06.03.01 Total−1.80−1.11−.70−.34−.20−.12Note.—LOD scores were computed with the assumption of a disease-gene frequency of 0.001, a penetrance rate of 95%, a phenocopy rate of 0.001 (as used in the original analysis), and marker-allele frequencies estimated by maximum likelihood. The combined LOD score for D9S286 at θ=0 is 3.49 when the disease-gene frequency is increased to 0.003 and the phenocopy rate is increased to 0.005 and is 3.24 with a disease-gene frequency of 0.003, a phenocopy rate of 0.05, and a penetrance rate of 0.95. Open table in a new tab Note.— LOD scores were computed with the assumption of a disease-gene frequency of 0.001, a penetrance rate of 95%, a phenocopy rate of 0.001 (as used in the original analysis), and marker-allele frequencies estimated by maximum likelihood. The combined LOD score for D9S286 at θ=0 is 3.49 when the disease-gene frequency is increased to 0.003 and the phenocopy rate is increased to 0.005 and is 3.24 with a disease-gene frequency of 0.003, a phenocopy rate of 0.05, and a penetrance rate of 0.95. Model-Based Linkage Analysis: In our study (Chen et al. Chen et al., 2004Chen S Ondo WG Rao S Li L Chen Q Wang Q Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2004; 74: 876-885Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar), we calculated the LOD scores using the program Linkage Package 5.2 (MLINK) directly connected to the pedigree program Cyrillic 2, which apparently treated twins as full siblings. This treatment leads to the upper-limit estimation of LOD scores. We have now recalculated the LOD scores by deleting the data from one member of the twin pair in the analysis. The linkage remains significant (table 1). For model-based linkage analysis of one or a few pedigrees, the assumptions of the disease-gene frequency, marker-allele frequencies, penetrance, and phenocopy rates are largely based on educated guesses. These assumptions may vary among different research groups, since the genetic architecture of the disease is not clear in most cases. A disease-gene frequency of 0.026, as suggested by Ray and Weeks (Ray and Weeks, 2005Ray A Weeks DE No convincing evidence of linkage for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2005; 76 (in this issue): 705-707Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar), is too high, since RLS is genetically highly heterogeneous; many genes may be involved in development of RLS, and the frequency of one specific gene—for example, the chromosome 9p RLS gene—is expected to be much lower. The assumption made by Ray and Weeks (Ray and Weeks, 2005Ray A Weeks DE No convincing evidence of linkage for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2005; 76 (in this issue): 705-707Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar) is not realistic unless a single gene is the cause of the disorder in all patients with RLS (5%–12% of the population). To date, two other RLS loci have already been mapped to chromosomes 12 and 14, and many families do not link to the three known RLS loci (Desautels et al. Desautels et al., 2001Desautels A Turecki G Montplaisir J Sequeira A Verner A Rouleau GA Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q.Am J Hum Genet. 2001; 69: 1266-1270Abstract Full Text Full Text PDF PubMed Scopus (237) Google Scholar; Bonati et al. Bonati et al., 2003Bonati MT Ferini-Strambi L Aridon P Oldani A Zucconi M Casari G Autosomal dominant restless legs syndrome maps on chromosome 14q.Brain. 2003; 126: 1485-1492Crossref PubMed Scopus (234) Google Scholar; Chen et al. Chen et al., 2004Chen S Ondo WG Rao S Li L Chen Q Wang Q Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.Am J Hum Genet. 2004; 74: 876-885Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar). To investigate whether the 1/n method (i.e., the assumption that there are equal allelic frequencies and that n equals the total number of alleles observed in the families studied) could lead to false evidence of linkage for these particular data, we calculated the LOD scores for our genotyping data by using the allele frequencies that were estimated with the maximum-likelihood method. The linkage for the 9p RLS linkage remains significant, with a combined two-point LOD score of 3.53 at D9S286 (table 1) and a multipoint LOD score of 3.56 (fig. 1). (Note that these LOD scores were obtained when one member of the twin pair was removed from the analysis, and the overall LOD scores slightly increased when actual allele frequencies were used, as compared with the use of 1/n allele frequencies: 3.53 vs. 3.52 for D9S286 and 3.10 vs. 2.95 for D9S274.) These results indicate that the LOD scores for the 9p RLS linkage do not change much if the maximum-likelihood estimates of the sample allele frequencies are used. For model-based linkage analysis, genotyping is commonly performed for multiple mid- to large-size families, but linkage at a specific locus may be identified and reported in a subset of the families, since other families may be associated with different disease genes. We agree that model-based linkage analysis can also be performed for our complete genotyping data with the assumption of heterogeneity. To calculate heterogeneity LOD (HLOD) scores, we used the GeneHunter-Plus program, which maximizes the LOD scores over both recombination fraction θ and admixture parameter α. The HLOD score at the 9p RLS locus, with the assumption of autosomal dominant inheritance, reached 2.31. Similar results were obtained with the program HOMOG (HLOD = 2.46, with the assumption of autosomal dominant inheritance). These results are consistent with our original conclusion of the identification of an RLS locus on chromosome 9p24-22. In summary, we feel that our evidence of genetic linkage for RLS on chromosome 9p is methodologically sound, and our finding is buttressed by the independent replication in a different population.

No Evidence for a Familial Breast Cancer Susceptibility Gene at Chromosome 13q21 in Swedish Breast Cancer Families

Candidate Locus Analysis of the TERT – CLPTM1L Cancer Risk Region on Chromosome 5p15 Identifies Multiple Independent Variants Associated with Endometrial Cancer Risk

No Mutations in the BACH1 Gene in BRCA1 and BRCA2 Negative Breast‐cancer Families Linked to 17Q22

Swedish Genome-Wide Haplotype Association Analysis Suggests Breast Cancer Loci with Varying Risk-Modifying Effects

PHIP - a Novel Candidate Breast Cancer Susceptibility Locus on 6Q14.1.

A Region Close to Tp53 Shows LOH in Familial Breast Cancer.

A Breast Cancer Candidate Locus at 6q Narrowed to 6q15-q21

Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk

Evidence for a prostate cancer susceptibility locus on the X chromosome.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general …

Fine Scale Mapping of the Breast Cancer 16q12 Locus.

Common Non-Synonymous SNPs Associated with Breast Cancer Susceptibility: Findings from the Breast Cancer Association Consortium

Novel breast cancer susceptibility loci under linkage peaks identified in African ancestry consortia

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11

Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression Through Long-Range Enhancers.

Common Functional Mechanisms Underlying Pleiotropy At The 19p13.1 Breast And Ovarian Cancer Cusceptibility Locus

Fine-mapping Identi Fi Es Two Additional Breast Cancer Susceptibility Loci at 9 Q 31 . 2

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers

Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression

Reply to Ray and Weeks: Linkage for Restless Legs Syndrome on Chromosome 9p is Significant

Genome-Wide Association Study Identifies Breast Cancer Risk Variant at 10q21.2: Results from the Asia Breast Cancer Consortium